anonymous
Guest
anonymous
Guest
Now sitting stagnate at 5.56. This will never grow. Wasn't this stock at $78.00 in 2020? What happened?
Now sitting stagnate at 5.56. This will never grow. Wasn't this stock at $78.00 in 2020? What happened?
Ok, Karen.Things aren't going well in the field. Everyone has resumes out and actively looking. Outcomes is looming like an upcoming tornado.
Dumb. Ass. Karen.The stock staggered across the finish line at 5.56. Pretty pathetic!! No runway here. What in God's name are the Scientifall Hired Customer Facing now Lipid Experts doing???
Keep us posted, Karen.The after hours trading has been week. Will see what today shows. Esperion never performs on a Friday especially after such a shitty week so far. Look for more misery in the coming weeks.
I just threw up in my mouth..so now it's market gyrations. Shit that is pretty creative and also ridiculous. This will be a dud. Go long!! Lolololol. What a shit show.
Market swings and sector gyrations are often plausible reasons for short term stock price moves; Additionally, profit taking and tax ramifications are extraneous factors that influence near term valuations. That being said, you are gonna want to BE LONG on ESPR before March 4th; the CLEAR outcomes data release is a market moving opportunity that can shape the lipid treatment standard of care/guidelines over the coming decade. The 20 minutes of fame and fortune afforded to ESPR will further establish the legacy of the lipid company! Be long and belong to the team that is about to embark on a life changing journey!
Such a sanctimonious prick, Mother Karen OsteenLord forgive their ignorance as they not know what they do. Stupidity is a disease and there's no cure. Just like the idiots in Ann Arbor. Nothing has gone right from the start.
Sure, Karen, you know "Steve"? The least that you morons can do is correctly spell his name.Nobody gives a shit what Steve says. This will be another disappointment. Reduction in death?? All cause mortality? Side effects?? Will wait for the grown from the audience when they here the results.
It does make sense to be long going into the presser, we already know the results are positive, it’s really just a matter of how much upside we get. With Nissan delivering the message we can be confident that there is a lot of credibility behind the results, and generally speaking what he says becomes a market shaping doctrine. All hands on deck as we create a new treatment paradigm, looking forward to the pop and sizzle!
Ok, Karen.This was the Ann Arbor lackey spelling Steve name wrong. Your insulting one of your own. It's Nissen for all you well informed Scientific Hires.